Alrestatin

This classification denotes an aldose reductase inhibitor with the molecular formula C14H9NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 515DHK15LG, chemically known as 2,3-dihydro-1,3-dioxo-1h-benz(de)isochiolin-2-essigsaeure but more generally known as alrestatin, which bears US NIH Compound Identifier 2120. Alrestatin most often comes in natrium and sodium forms. European Medicines Agency schedules Alrestatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05373MIG. The term ALRESTATIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 30, No. 10 1976, List 16). ALRESTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule alrestatin under HS 29251995 and SITC 51482. As of Q4 2014, ALRESTATIN remains US FDA's Preferred Term for this commodity. Alrestatin bears US NLM identifiers UMLS ID C0051486 and NCI Concept Code C72917. SMILES: O=C1N(C(=O)C2C3C1CCCC3CCC2)CC(=O)O.